Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KYNB stock hub

Kyntra Bio, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KYNBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

28.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KYNB

In the news

Latest news · KYNB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/E0.2

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KYNB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000921299
Company name	Kyntra Bio, Inc.
Country	United States
Country code	US
Cusip	31572Q881
Employees	34
Employees Change	-191%
Employees Change Percent	-84.89
Enterprise value	$-41.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US31572Q8814
Last refreshed	2026-05-10
Market cap	$28.1M
Market cap category	Nano-Cap
Price	$6.95
Price currency	USD
Rev Per Employee	189,411.76x
Sector	Healthcare
Symbol	KYNB
Website	https://www.kyntrabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	652.06%
FCF yield	-17.1%
P/B ratio	6.29x
P/E ratio	0.15x
P/S ratio	4.37x
PS Forward	5.33x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-273.8%
Gross Profit	$-17.6M
Net Income	$183.5M
Net Income Growth Years	3%
Pretax Margin	-905.19%
Profit Margin	2,848.63%
Profit Per Employee	$5.4M
Profitable Years	1
ROA	-16.96
Roa5y	-27.5
ROCE	-50.18

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-33.24%
Cagr1y	-14.73%
Cagr3y	-74.81%
Cagr5y	-57.58%
EPS Growth Years	3
Revenue Growth	-78.26x
Revenue Growth Q	-59.27x
Revenue Growth Years	0x
Revenue Growth3 Y	-64.23x
Revenue Growth5 Y	-48.42x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.04
Assets	$119.6M
Cash	$89M
Current Assets	$99.1M
Current Liabilities	$29.2M
Debt	$19.6M
Debt Equity	$4.37
Equity	$4.5M
Interest Coverage	-5.18
Liabilities	$115.1M
Long Term Assets	$20.5M
Long Term Liabilities	$85.9M
Net Cash	$69.4M
Net Cash By Market Cap	$247
Net Debt Equity	$-15.51
Tangible Book Value	$-30M
Tangible Book Value Per Share	$-7.42
WACC	20.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.39
Inventory Turnover	6.98
Net Working Capital	$-19.1M
Quick ratio	3.19
Working Capital	$69.8M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.02%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-98.24%
1Y total return	-14.72%
200-day SMA	8.94
3Y total return	-98.4%
50-day SMA	7.05
50-day SMA vs 200-day SMA	50under200
5Y total return	-98.63%
All Time High	1,713.8
All Time High Change	-99.59%
All Time High Date	2018-07-09
All Time Low	4.5
All Time Low Change	54.44%
All Time Low Date	2024-11-13
ATR	0.24
Beta	1.04
Beta1y	0.97
Beta2y	0.87
Ch YTD	-20.84
High	7.09
High52	12.6
High52 Date	2025-09-03
High52ch	-44.84%
Low	6.95
Low52	4.85
Low52 Date	2025-06-30
Low52ch	43.3%
Ma50ch	-1.36%
Price vs 200-day SMA	-22.23%
RSI	45.02
RSI Monthly	33.96
RSI Weekly	40.76
Sharpe ratio	0.08x
Sortino ratio	0.21
Total Return	-1.02%
Tr YTD	-20.84
Tr1m	0.43%
Tr1w	-1.97%
Tr3m	-15.45%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-3.36
Earnings Revenue Estimate	1,556,000x
Earnings Revenue Estimate Growth	-43.19x
Operating Income	$-45.3M
Operating margin	-704.1

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,563,953%
Float Percent	88.04%
Net Borrowing	-80,560,000
Shares Insiders	2.08%
Shares Institutions	17.59%
Shares Out	4,048,112
Shares Qo Q	0.05%
Shares Yo Y	1.02%
Short Float	3.17%
Short Ratio	3.86
Short Shares	2.79

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-11.4M
Average Volume	8,090.2x
Bv Per Share	-7.42
CAPEX	$-38,000
Ch10y	-98.24
Ch1m	0.43
Ch1w	-1.97
Ch1y	-14.72
Ch3m	-15.45
Ch3y	-98.4
Ch5y	-98.63
Ch6m	-36.99
Change	-2.11%
Change From Open	-1.42
Close	7.1
Days Gap	-0.7
Depreciation Amortization	748,000
Dollar Volume	33,858.9
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$-45.3M
EBITDA	$-44.6M
EPS	$45.38
F Score	4
FCF	$-4.8M
FCF EV Yield	11.66x
FCF Per Share	$-1.19
Financing CF	-86,028,000
Fiscal Year End	December
Founded	1,993
Income Tax	$-90,000
Investing CF	35,419,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-16
Last Report Date	2025-12-31
Last Split Date	2025-06-17
Last Split Type	Reverse
Ma150	8.48
Ma150ch	-18%
Ma20	7.14
Ma20ch	-2.65%
Net CF	-54,306,000
Next Earnings Date	2026-05-11
Open	7.05
Optionable	Yes
Position In Range	0
Post Close	6.95
Postmarket Change Percent	0.13
Postmarket Price	$6.96
Price Date	2026-05-08
Relative Volume	0.6x
Revenue	6,440,000x
SBC By Revenue	102.11x
Share Based Comp	6,576,000
Tax By Revenue	-1.4x
Tr6m	-36.99%
Us State	California
Volume	4,871.8
Z Score	-20.27

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KYNB pay a dividend?

Capital-return profile for this ticker.

Performance

KYNB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KYNB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.6%

Float: +88.0% of shares outstanding

Insider ownership

+2.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KYNB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.0

Neutral momentum band

Price vs 200-day MA

-22.2%

50/200-day relationship not available

Beta (5Y)

1.04

Moves roughly with the market

Sharpe ratio

0.08

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KYNB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KYNB stock rating?

Kyntra Bio, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KYNB analysis?

The full report lives at /stocks/KYNB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KYNB?

The latest report frames KYNB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KYNB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.